Using medicines beyond licence

Similar documents
Use of unlicensed medicines and off-label uses

Spinal cord stimulation for pain Information for patients

Opioids for persistent pain: Information for patients. The British Pain Society's

Planning for a time when you cannot make decisions for yourself

Review of National Disability Insurance Scheme Decisions Practice Direction

Patient information. Your Spinal Anaesthetic. Directorate of Anaesthesia PIF 763/V4

Oral N-Acetyl CystieneTablets. Patient Information

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE

High dose antipsychotic therapy

University College Hospital

Quality, Safety and Sourcing in Unlicensed Medicines

Excellent Care with Compassion

DECISION QUALITY WORKSHEET TREATMENTS FOR DEPRESSION

Guidance for Witnesses

Mycophenolate treatment for respiratory conditions. Information for patients Respiratory Medicine - Asthma

MODULE 1: BASIC DRUG KNOWLEDGE

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CABOZANTINIB. Patient s first names.

Buprenorphine treatment

Patient Guide. This PATIENT GUIDE comes with your Binosto 70mg Effervescent Tablets pack. Please read it carefully.

SECTION 8: ACCIDENTAL AWARENESS DURING GENERAL ANAESTHESIA

Advance Statements. What is an Advance Statement? Information Line: Website: compassionindying.org.uk

Lambeth Early Onset (LEO) Team

Safeguarding adults: mediation and family group conferences: Information for people who use services

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID. Patient s first names.

HIV PrEP in Ireland. Information booklet for people who are accessing PrEP themselves or are considering accessing PrEP

Rivaroxaban to prevent blood clots for patients who have a lower limb plaster cast. Information for patients Pharmacy

About general anaesthesia Day Surgery Unit Patient Information Leaflet

Consent to research. A draft for consultation

PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1

Medicines in Scotland: What s the right treatment for me? Information for patients and the public

Methotrexate for inflammatory bowel disease: what you need to know

GOC GUIDANCE FOR WITNESSES IN FITNESS TO PRACTISE COMMITTEE HEARINGS

Your child s general anaesthetic for dental treatment

Opioid Type Pain Killers

Guide to Professional Conduct and Ethics for Registered Medical Practitioners. Relationships between doctors and industry Frequently Asked Questions

Frequently asked questions

Pain relief at home. Information for patients, families and carers

Falls: the assessment and prevention of falls in older people

Strong bones after 50 Fracture liaison services explained A guide for patients, carers and families

Lidocaine Hydrochloride BP 2% w/v in Lutrol F127 24% w/v Sterile Gel. Information for patients Pharmacy

How Clinical Trials Work

Type 1 diabetes and exams

Our plan for giving better care to people with dementia Oxleas Dementia

SHARED CARE PRESCRIBING GUIDELINE

Correcting a squint (adult) Brought to you in association with EIDO Healthcare and endorsed by the Royal College of Surgeons England.

PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FERRERI / IELSG PROTOCOL. Patient s first names. Date of birth

Strong bones after 50 Fracture liaison services explained A guide for patients, carers and families

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE (HIGH DOSE)

Incisionless surgery to correct protruding ears

Electroconvulsive Therapy (ECT) Patient Information Leaflet

Welcome to the Community Children and Young People s Service. Information you will find useful during your contact with the service

Adult ADHD Service Patient Information Leaflet

Electroconvulsive Therapy (ECT) Patient Information Leaflet

Keyhole surgery to flush out the knee joint and remove damaged tissue to treat osteoarthritis

Tranexamic acid. Information for parents and carers

NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION

How is the introduction of a new medicine regulated in the UK?

Deactivating the shock function of an implantable cardioverter defibrillator (ICD) towards the end of life

Guidance for Pharmacists on Safe Supply of Oral Methotrexate

Patient information. Breast Reconstruction using an Expander and Implant Breast Services Directorate PIF 110 V5

Getting the best from the medicines you buy

Our plan for making the lives of people with autism and their families and carers better

Atrial Fibrillation and Anticoagulants

Dear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE

NAS NATIONAL AUDIT OF SCHIZOPHRENIA. Second National Audit of Schizophrenia What you need to know

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB. Patient s first names. Date of birth.

medicines and side effects

The Children s Hospital, Oxford Sedation for clinical procedures Information for parents and carers

Mental capacity and mental illness

URGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU

Tranexamic acid. Information for parents and carers

Patient information sheet: BuTrans Patch This information should be read in conjunction with the Taking Opioids for pain information leaflet

Pandemic influenza Recommendations on the use of antiviral medicines for pregnant women, women who are breastfeeding and children under the age of

Regional Anaesthetic for Arm and Hand Operations (Upper Limb Surgery)

Methotrexate. Information for patients. Paediatric Rheumatology. Feedback

Electroconvulsive Therapy (ECT) Patient Information Leaflet

Herbal medicines and supplements for cancer patients

Deciding whether a person has the capacity to make a decision the Mental Capacity Act 2005

If you or one of your relatives has Parkinson s, you may want to know

Mild memory problems

A practical guide to living with and after cancer. Helping you take an active role in your cancer care

Your spinal anaesthetic

MENTAL HEALTH. Power of Attorney

Consultation Questionnaire

Medication Use safety Training FOR SENIORS

Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone

Sexual Assault: When Sex is Not OK

Smile. Your dental team have check ups too

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

Mycophenolate mofetil: risks of miscarriage and birth defects. Patient guide

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group

This information explains the advice about supporting people with dementia and their carers that is set out in NICE SCIE clinical guideline 42.

GOC Guidance for Witnesses in Fitness to Practise Committee Hearings

COPYRIGHTED MATERIAL. Introduction

Issue: March 2016 PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES

This information explains the advice about Crohn's disease that is set out in NICE guideline CG152.

swine flu vaccination:

what you need flu. Protect yourself and others.

Cancer and Advance Care Planning You ve been diagnosed with cancer. Now what?

You and your anaesthetic Information to help patients prepare for an anaesthetic

Transcription:

Using medicines beyond licence Information for patients Prepared on behalf of the Association for Palliative Medicine and the British Pain Society. November 2005 To be reviewed in November 2008. Copyright: The Association for Palliative Medicine and the British Pain Society, 2005 i

Published by: The British Pain Society 21 Portland Place London W1B 1PY. Website: www.britishpainsociety.org First published by the Pain Society, January 2003 First revised edition, November 2005 ISBN 0-9546703-9-6

Contents Introduction 1 What is the licensing process? 1 Why are medicines sometimes used outside their licence? 1 Can doctors prescribe medicines outside their licence? 3 How will I know if the medicines I have been prescribed are outside their licence? 3 What should I do if I m not sure about my medicines? 4 The working party 5

Introduction You might have been given this leaflet because your doctor has prescribed a medicine for you that you need to use beyond the conditions of its licence (called using a medicine outside its licence). Your medical team will have thought carefully about which medicines are best for you in your situation. This leaflet will help you to understand some important aspects of medicine licensing regulations and how these issues might affect you. If you have any questions about any aspect of your medication, you should ask your health-care team. What is the licensing process? Most medicines prescribed by a doctor or bought over the counter from a pharmacist have a licence for use. When a manufacturer produces and sells any medicine in the UK, they must first get a licence (called a product licence or marketing authorisation) from the Medicines and Health products Regulatory Agency. The licence describes: the way in which the drug can be given; what conditions it can be used to treat; the doses that can be given; and which patients can be treated. To get a licence, the manufacturer must prove that the medicine: works to treat the condition for which it is to be given; does not have too many side effects or risks; and has been made to a high standard. It is very expensive for a manufacturer to get a licence. The licence is there to restrict the way in which the manufacturer promotes and sells the drug. The licensing process does not restrict any doctor from prescribing the medicine, as long as the doctor is sure that the medicine is safe and effective for that patient. 1

Why are medicines sometimes used outside their licence? Sometimes a medicine has been licensed for a certain use and later experience or research shows that it works for other conditions. The medicine manufacturer does not have to apply to the Medicines and Health products Regulatory Agency to try to have the more recent information added to the licence. In some situations, it is not economical for the manufacturer to get or extend a licence. By law, the manufacturer must include a patient information leaflet with all medicines. This leaflet must be given to you and it must only contain the information from the licence. So, some of the uses for the medicine will not appear on the patient information leaflet. This can be confusing for patients and their carers. An example of this is the common use of antidepressant medicines to treat pain. These medicines have a licence to be used for depression but not for pain so the information leaflet will talk about depression and not refer to pain. This happens purely because the patient information leaflet reflects the licence. If you are given an antidepressant drug, it does not necessarily mean that your doctor has decided you are depressed. If your doctor thought you were depressed, they would have discussed this with you. Examples of other circumstances where medicines may be used outside their licence include: medicines licensed for use in certain age groups that are used in a different age group; medicines licensed for use at one dose that are used at a different dose; medicines licensed for use by injection that are given as tablets; and 2

medicines that do not have a licence for a disease because it is so rare. Can doctors prescribe medicines outside their licence? It is legal for a doctor to prescribe a medicine outside its licence. A pharmacist can legally dispense and a nurse can legally administer (give) these medicines. It is common for medicines to be used in this way outside their licence. For example, in specialist palliative care (specialist services that look after patients at the end of their life), up to two thirds of patients receive medicines that are not licensed for their condition. Doctors usually only do this when there is clinical experience or research to support the use and when there is no suitable licensed alternative medicine. How will I know if the medicines I have been prescribed are outside their licence? Your doctor, pharmacist or nurse may tell you this. However, in pain management and palliative care, it is very common for medicines to be used outside their licence so your health-care team may not refer to this specifically. The health-care team has a lot of experience in using medicines in this way. They will have considered very carefully what is best for you. It is very important that you receive a clear explanation of why you are taking any medicines, how you should take your medicines, and what benefits and side effects you might expect. This is just as important when medicines are used according to the licence as when they are used outside their licence. As with all medicines, if you experience a side effect from this medicine, you should tell your health-care team. Your health-care team should get your verbal agreement, whenever possible, before prescribing any medicine. It is often unnecessary to do anything else when prescribing medicines outside their licence. 3

What should I do if I m not sure about my medicines? If you are still not sure about your medicines, or are worried about anything after reading this leaflet, please talk to your health-care team. The doctors, pharmacists and nurses will be able to answer your questions and give you any more information you need. You can download copies of this leaflet from: www.britishpainsociety.org; and www.palliative-medicine.org. 4

The working party Below is a list of the members of the joint working party of the Association for Palliative Medicine and the Pain Society (now known as the British Pain Society), who worked on this information about using drugs beyond licence in palliative care and pain management. Chairmen Dr M Bennett, Consultant in Palliative Medicine Association for Palliative Medicine (APM) Dr K H Simpson, Consultant in Pain Medicine The Pain Society Members Professor S Ahmedzai, Professor of Palliative Medicine Association for Palliative Medicine Mrs E Brain, Lay Member Patient Liaison Committee of The Pain Society Dr M Branthwaite, Retired Barrister Former consultant in Anaesthesia, Intensive Care and Respiratory Medicine Dr P D Collins, Consultant in Pain Medicine The Pain Society Mrs S Conroy, Lecturer in Paediatric Clinical Pharmacy Dr A Franks, Consultant in Public Health Medicine Deputy Medical Director, Acute Hospital Trust Dr D M Justins, Consultant in Pain Medicine The Pain Society Dr C Stannard, Consultant in Pain Medicine The Pain Society Mrs T Towell, Nurse Consultant Dr J Wedley, Consultant in Pain Medicine Association of Anaesthetists of Great Britain and Ireland 5

6

7

21 Portland Place London W1B 1PY T: 020 7631 8870 F: 020 7323 2015 www.britishpainsociety.org E: info@britishpainsociety.org